The systemic immune inflammation index (SII) has been demonstrated to be highly significant in predicting the prognosis of patients with malignant tumors, including pancreatic carcinoma, breast cancer, hepatocellular carcinoma, and colorectal cancer [ 21 , 22 ].
← all excerpts
Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.
1
—
—